Pain Management

Study investigators suggest that there is a higher prevalence of pain and treatment needs in this small population.

A panel released recommendations in accordance with decades of a changing landscape in acetaminophen poisoning and due to an absence of agreed upon guidelines in the space.

No major changes were found in overdose behaviors among individuals who received take-home naloxone.

Author of the book The Journey’s End discusses how extending life at all costs takes away time that patients could be spending with their families during the last moments of their life.

The approval of RiVive naloxone hydrochloride nasal spray for nonprescription use provides another tool to help quickly reverse the effects of opioid overdose.

The data could inform how non–steroidal anti-inflammatory drug-mediated mitochondrial uncoupling could affect other diseases.

Nonpharmacologic and nonopioid treatments associated with improvements in pain and/or function that appear comparable to opioid treatments.

Patients can employ numerous measures to alleviate pain, improve mobility, and boost overall health-related quality of life.

With no treatments currently FDA approved, patients arrive at the hospital with no options for treatment beside waiting for the intoxication to pass.

Technicians should take advantage of opportunities to work at a higher level of practice, build their careers.

The drug is available in 2 formulations, including a weekly injection with a lower dose than previously available as well as a monthly injection.

The attitudes of community-based opioid use disorder treatment center staff toward the emergency department as a site of initiation were varied, with some feeling that emergency department-initiated buprenorphine may attract patients who were not experiencing life-threatening emergencies.

Christina Madison sat down with Walter Oronsaye, known as the Phit Pharmacist, to discuss over prescribing as well as social media as a tool for pharmacists.

Common chronic pain conditions included in the analysis were fibromyalgia, neuropathic pain, and musculoskeletal pain.

Health care professionals should educate patients that it is possible to effectively manage pain without opioids.

A novel collaboration between the University of Pennsylvania and US Anesthesia Partners is working to drive evidence-based change in benzodiazepine use.

During a fireside chat, USP CEO Ronald T. Piervincenzi, PhD, and the Honorable Dr. Oh Yu-Kyoung, Minister of MFDS, Republic of Korea, discuss interruptions to the medical supply chain and the interventions used.

Proposed rules would permit a telehealth provider to prescribe only up to a 30-day supply of a Schedule III-V non-narcotic controlled substance or buprenorphine through telehealth without the patient first being evaluated in person by a provider.

To eliminate the existing stigma in the community, addiction must be recognized as a treatable condition rather than an immoral act.

Host Christina Madison, PharmD, BCACP, AAHIVP, sat down with Jeffrey Bratberg, PharmD, FAPhA, a clinical professor in the college of pharmacy at the University of Rhode Island

Analysis shows that babies of mothers who used drugs while pregnant were shorter at birth and weighed less during the breastfeeding stage compared with non-drug-exposed infants.

To build a brighter, healthier, and more equitable future for all US citizens, there is an indisputable need to decriminalize psychedelic medicines.

Analysis indicates that there was a larger increase of filled prescriptions for individuals who delivered by cesarean birth.

Some specialty pharmacy programs are even using electronic medical records to send survey tools to patients.

Before tapering patients treated for cancer off of opioids, care providers should first establish what the goals of tapering are.

FDA action allows for OTC naloxone (Narcan) to be sold directly to consumers in pharmacies, convenience stores, grocery stores, gas stations, and online.

Currently, APHA has a policy on its books that opposes both drug legalization and decriminalization.

More and more data, both from real world analyses and clinical trials, are shedding light on the effective uses of cannabis, as well as the contraindications for its use in patients.

Specifically, non-opioids are often preferred for the management of subacute and chronic pain because of their safety profiles.

As the risk of respiratory depression is elevated with opioid use, the risk of complications from COVID-19 is increased in patients with opioid use disorder.